HTG Molecular Diagnostics (HTGM) Given a $6.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $6.00 target price on HTG Molecular Diagnostics (NASDAQ:HTGM) in a report released on Wednesday morning. The firm currently has a buy rating on the medical research company’s stock.

Other research analysts have also recently issued reports about the company. Zacks Investment Research upgraded HTG Molecular Diagnostics from a hold rating to a buy rating and set a $2.50 price objective for the company in a research note on Wednesday, November 15th. ValuEngine upgraded HTG Molecular Diagnostics from a strong sell rating to a sell rating in a research report on Friday, September 1st. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. HTG Molecular Diagnostics currently has an average rating of Hold and a consensus price target of $5.25.

HTG Molecular Diagnostics (NASDAQ HTGM) opened at $2.07 on Wednesday. HTG Molecular Diagnostics has a 12 month low of $1.20 and a 12 month high of $13.25. The stock has a market capitalization of $22.21 and a PE ratio of -0.81.

An institutional investor recently raised its position in HTG Molecular Diagnostics stock. Vanguard Group Inc. grew its holdings in HTG Molecular Diagnostics Inc (NASDAQ:HTGM) by 38.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 135,234 shares of the medical research company’s stock after buying an additional 37,841 shares during the quarter. Vanguard Group Inc. owned 1.42% of HTG Molecular Diagnostics worth $359,000 as of its most recent SEC filing. Institutional investors and hedge funds own 15.15% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “HTG Molecular Diagnostics (HTGM) Given a $6.00 Price Target by HC Wainwright Analysts” was originally reported by Community Financial News and is owned by of Community Financial News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

What are top analysts saying about HTG Molecular Diagnostics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for HTG Molecular Diagnostics and related companies.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit